William Hayes - REDFILED (Page 6)

CIEN

CIENA Revenue Jumps 37% to $1.67B as AI Drives Optical Demand

Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.

Apogee Therapeutics develops antibody therapies for inflammatory and immunology diseases.

APGE

APOGEE THERAPEUTICS Buyout Closes as Shares Head for Delisting

An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.

Shay Banon, co-founder and Chief Technology Officer of Elastic.

ESTC

ELASTIC Founder Shay Banon Sells $44.5M in Shares Over Three Days

Elastic's CTO and co-founder disposed of about 476,000 ordinary shares between August 31 and September 2, cutting his stake to roughly 1.58 million shares.

Aura Minerals operates gold and copper assets in the Americas.

AUGO

Aura Minerals Director Sells $10.4 Million of Shares in Open Market

A Form 4 shows director Bruno Sousa Mauad sold 127,500 Aura Minerals shares at $81.20 apiece on Aug. 31, cutting his stake by more than 40%.

CRWD

CrowdStrike Co-Founder Kurtz and Director Gandhi Sell $8.8M in Stock

Two CrowdStrike insiders sold a combined 40,000 Class A shares on Aug. 31 and Sept. 1 at prices between roughly $213 and $234.

Sherif Foda, chief executive officer of National Energy Services Reunited.

NESR

NESR CEO Sherif Foda Sells $3.5M in Stock, Gifts 675,000 Shares

National Energy Services Reunited's chief executive sold 100,000 ordinary shares at $35.00 and transferred another 675,000 shares as a gift.

Laboratory research into pancreatic cancer, the disease targeted by the newly approved RAS inhibitor.

RVMD

FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.

An oral tablet formulation of the type newly approved for adults with dermatomyositis.

ROIV

FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults

The FDA has cleared Lisraya (brepocitinib) tablets, the first oral therapy specifically indicated for adults with dermatomyositis.

Polycythemia vera causes the body to produce too many red blood cells.

PTGX

FDA Approves Mimrylo (Rusfertide), First Hepcidin Mimetic for Polycythemia Vera

The FDA has cleared Mimrylo (rusfertide) for adults with polycythemia vera, calling it the first drug of its kind for the rare blood disorder.

A wearable continuous glucose monitoring sensor worn on the upper arm.

ABT

FDA Authorizes First Dual Glucose and Ketone Wearable, Abbott's Libre Duo

The FDA cleared the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people with diabetes aged 2 and older.

Definitive Healthcare is a provider of healthcare market data and analytics.

DH

Advent Offers $1.02 a Share to Take Definitive Healthcare (DH) Private

A special committee of independent directors confirmed a non-binding all-cash proposal from Advent International for all shares it does not already own.

ABI

Abcourt Closes US$10M Debenture Upsize With Glencore, Repays Nebari Loan

Abcourt Mines lifted its Glencore senior secured debenture to US$40 million, drew US$19.875 million and repaid a US$12 million Nebari credit facility.